ALLIANCE PHARMA PLC

Regulatory Filings • Aug 18, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4851H

Alliance Pharma PLC

18 August 2016

For immediate release	18 August 2016

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Interim Results Analyst Meeting - Change of Time

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold the analyst presentation of its results for the six months ended 30 June 2016 at the revised time of 10.30am on Wednesday 14 September 2016.

The presentation will be held at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Sarah Robinson, Company Secretary
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKMGMRVNZGVZM